Logo image of CDNA

CAREDX INC (CDNA) Stock Fundamental Analysis

NASDAQ:CDNA - Nasdaq - US14167L1035 - Common Stock - Currency: USD

22.29  -1.09 (-4.66%)

After market: 22.18 -0.11 (-0.49%)

Fundamental Rating

5

Taking everything into account, CDNA scores 5 out of 10 in our fundamental rating. CDNA was compared to 571 industry peers in the Biotechnology industry. While CDNA has a great health rating, there are worries on its profitability. CDNA has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CDNA had positive earnings in the past year.
CDNA had a positive operating cash flow in the past year.
In the past 5 years CDNA always reported negative net income.
CDNA had negative operating cash flow in 4 of the past 5 years.
CDNA Yearly Net Income VS EBIT VS OCF VS FCFCDNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

With a decent Return On Assets value of -30.10%, CDNA is doing good in the industry, outperforming 67.67% of the companies in the same industry.
The Return On Equity of CDNA (-52.54%) is better than 64.30% of its industry peers.
Industry RankSector Rank
ROA -30.1%
ROE -52.54%
ROIC N/A
ROA(3y)-20.1%
ROA(5y)-15.97%
ROE(3y)-32.39%
ROE(5y)-25.23%
ROIC(3y)N/A
ROIC(5y)N/A
CDNA Yearly ROA, ROE, ROICCDNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800

1.3 Margins

The Gross Margin of CDNA (65.77%) is better than 81.53% of its industry peers.
CDNA's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CDNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.8%
GM growth 5Y2.25%
CDNA Yearly Profit, Operating, Gross MarginsCDNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

7

2. Health

2.1 Basic Checks

CDNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDNA has been reduced compared to 1 year ago.
CDNA has more shares outstanding than it did 5 years ago.
CDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CDNA Yearly Shares OutstandingCDNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CDNA Yearly Total Debt VS Total AssetsCDNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

CDNA has an Altman-Z score of 2.34. This is not the best score and indicates that CDNA is in the grey zone with still only limited risk for bankruptcy at the moment.
CDNA's Altman-Z score of 2.34 is fine compared to the rest of the industry. CDNA outperforms 72.29% of its industry peers.
There is no outstanding debt for CDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 2.34
ROIC/WACCN/A
WACC9.44%
CDNA Yearly LT Debt VS Equity VS FCFCDNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

CDNA has a Current Ratio of 4.10. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.10, CDNA is in line with its industry, outperforming 47.25% of the companies in the same industry.
CDNA has a Quick Ratio of 3.87. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
CDNA's Quick ratio of 3.87 is in line compared to the rest of the industry. CDNA outperforms 47.07% of its industry peers.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 3.87
CDNA Yearly Current Assets VS Current LiabilitesCDNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 135.19% over the past year.
CDNA shows a small growth in Revenue. In the last year, the Revenue has grown by 5.27%.
The Revenue has been growing by 29.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)135.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%177.78%
Revenue 1Y (TTM)5.27%
Revenue growth 3Y13.41%
Revenue growth 5Y29.62%
Sales Q2Q%23.35%

3.2 Future

The Earnings Per Share is expected to grow by 48.42% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 15.78% on average over the next years. This is quite good.
EPS Next Y179.69%
EPS Next 2Y71.07%
EPS Next 3Y50.33%
EPS Next 5Y48.42%
Revenue Next Year19.02%
Revenue Next 2Y15.21%
Revenue Next 3Y15.06%
Revenue Next 5Y15.78%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CDNA Yearly Revenue VS EstimatesCDNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
CDNA Yearly EPS VS EstimatesCDNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1 1.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 117.32, which means the current valuation is very expensive for CDNA.
CDNA's Price/Earnings ratio is rather cheap when compared to the industry. CDNA is cheaper than 92.54% of the companies in the same industry.
When comparing the Price/Earnings ratio of CDNA to the average of the S&P500 Index (29.62), we can say CDNA is valued expensively.
The Price/Forward Earnings ratio is 37.58, which means the current valuation is very expensive for CDNA.
Based on the Price/Forward Earnings ratio, CDNA is valued cheaply inside the industry as 92.36% of the companies are valued more expensively.
CDNA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.70.
Industry RankSector Rank
PE 117.32
Fwd PE 37.58
CDNA Price Earnings VS Forward Price EarningsCDNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CDNA is valued cheaper than 92.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF 972.67
EV/EBITDA N/A
CDNA Per share dataCDNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CDNA's earnings are expected to grow with 50.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.65
PEG (5Y)N/A
EPS Next 2Y71.07%
EPS Next 3Y50.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CDNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAREDX INC

NASDAQ:CDNA (2/21/2025, 8:06:40 PM)

After market: 22.18 -0.11 (-0.49%)

22.29

-1.09 (-4.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners99.98%
Inst Owner Change-86.27%
Ins Owners2.87%
Ins Owner Change1.73%
Market Cap1.20B
Analysts80
Price Target33.02 (48.14%)
Short Float %8.61%
Short Ratio5.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)771.38%
Min EPS beat(2)270.21%
Max EPS beat(2)1272.55%
EPS beat(4)4
Avg EPS beat(4)416.48%
Min EPS beat(4)37.44%
Max EPS beat(4)1272.55%
EPS beat(8)8
Avg EPS beat(8)223.11%
EPS beat(12)9
Avg EPS beat(12)123.64%
EPS beat(16)13
Avg EPS beat(16)310.8%
Revenue beat(2)2
Avg Revenue beat(2)17.11%
Min Revenue beat(2)0.91%
Max Revenue beat(2)33.31%
Revenue beat(4)4
Avg Revenue beat(4)11.77%
Min Revenue beat(4)0.91%
Max Revenue beat(4)33.31%
Revenue beat(8)6
Avg Revenue beat(8)9.43%
Revenue beat(12)6
Avg Revenue beat(12)5.36%
Revenue beat(16)10
Avg Revenue beat(16)5.22%
PT rev (1m)-3.97%
PT rev (3m)-3.97%
EPS NQ rev (1m)148.83%
EPS NQ rev (3m)148.83%
EPS NY rev (1m)18.11%
EPS NY rev (3m)34.1%
Revenue NQ rev (1m)2.38%
Revenue NQ rev (3m)2.38%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)0.8%
Valuation
Industry RankSector Rank
PE 117.32
Fwd PE 37.58
P/S 3.82
P/FCF 972.67
P/OCF 153.63
P/B 4.37
P/tB 6.21
EV/EBITDA N/A
EPS(TTM)0.19
EY0.85%
EPS(NY)0.59
Fwd EY2.66%
FCF(TTM)0.02
FCFY0.1%
OCF(TTM)0.15
OCFY0.65%
SpS5.83
BVpS5.1
TBVpS3.59
PEG (NY)0.65
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.1%
ROE -52.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.77%
FCFM 0.39%
ROA(3y)-20.1%
ROA(5y)-15.97%
ROE(3y)-32.39%
ROE(5y)-25.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.8%
GM growth 5Y2.25%
F-Score6
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 45.31%
Cap/Sales 2.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 3.87
Altman-Z 2.34
F-Score6
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)168.07%
Cap/Depr(5y)142.54%
Cap/Sales(3y)5.9%
Cap/Sales(5y)5.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%177.78%
EPS Next Y179.69%
EPS Next 2Y71.07%
EPS Next 3Y50.33%
EPS Next 5Y48.42%
Revenue 1Y (TTM)5.27%
Revenue growth 3Y13.41%
Revenue growth 5Y29.62%
Sales Q2Q%23.35%
Revenue Next Year19.02%
Revenue Next 2Y15.21%
Revenue Next 3Y15.06%
Revenue Next 5Y15.78%
EBIT growth 1Y40.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year145.86%
EBIT Next 3Y47.36%
EBIT Next 5Y41.1%
FCF growth 1Y102.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y127.54%
OCF growth 3YN/A
OCF growth 5YN/A